A single dose of an siRNA molecule reduces elevated lipoprotein(a) — a major, but to date, largely untreatable risk factor ...

CHICAGO — Lepodisiran, a small interfering RNA agent, lowered lipoprotein(a) levels at 180 days, with a reduction of more ...

Heart disease experts are hailing the results of a clinical trial showed a strongly positive performance by a drug that ...

Discover how the experimental drug lepodisiran dramatically lowers lipoprotein(a) levels, potentially transforming treatment ...

Eli Lilly reports 94% Lp(a) reduction with lepodisiran in Phase 2 trials, targeting inherited heart disease risk.

The Phase II study found that lepodisiran significantly reduced levels of genetically inherited cardiovascular risk factor.

Food additive mixtures commonly found in diet drinks, soups, dairy desserts and sauces may slightly increase a person's risk ...

Eli Lilly has linked lepodisiran to sustained reductions in a cardiovascular disease risk factor for nearly 1.5 years, ...

Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) ...

A new drug in clinical trials is showing promise in lowering a key genetic risk factor for heart attacks and ...

Lepodisiran is being developed by biotech giant Eli Lilly & Co. (LLY), a stock that’s in my model portfolio. Here’s the tale of this new drug…how it could help millions of heart-ailment sufferers…and ...

The safety and efficacy of lepodisiran, an extended-duration, small interfering RNA targeting hepatic synthesis of lipoprotein(a), are unknown. We randomly assigned participants in a 1:2:2:2:2 ...